Pembrolizumab Injection [Keytruda]

Phase 1

Pembrolizumab Injection [Keytruda] is one of 6 therapeutic programs targeting Advanced Melanoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Advanced MelanomaActive, not recruiting

Advanced MelanomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

6 competitors in Advanced Melanoma

#DrugCompanyPhaseTrials

Opdivo

Bristol-Myers Squibb

Phase 3

3 2

Keytruda

Merck & Co.

Phase 3

3 3

Vusolimogene Oderparepvec

YYana Najjar

Phase 3

1 4

Glucophage

EMD Serono

Phase 1

1 5

Pembrolizumab Injection [Keytruda]

YYana Najjar

Phase 1

1 6

T3011

IImmVira Pharma Co. Ltd

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

Phase 1Active, not recruiting

Advanced Melanoma

NCT03311308

Clinical

Trials by Indication[1]

Advanced Melanoma1 trial

Profiling and Reversing Metabolic Insufficiency in the Tumor Microenvironment in Advanced Melanoma: A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma

Active, not recruiting·YYana Najjar·Phase 1·NCT03311308·23 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Pembrolizumab Injection [Keytruda]. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Pembrolizumab Injection [Keytruda]. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Yana Najjar company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: YYana Najjar

Pembrolizumab Injection [Keytruda]

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2029

Trials by Indication[1]

Advanced Melanoma1 trial

References

Drug Info

Quick Facts

Related News